SANTA MONICA, Calif. , May 12, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended March 31, 2020 , and provided a

SANTA MONICA, Calif. , April 28, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it will report its financial results for the first quarter ended

SANTA MONICA, Calif. , March 04, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the fourth quarter and year ended December 31,

SANTA MONICA, Calif. , Feb. 24, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it will report its financial results for the fourth quarter and year

SANTA MONICA, Calif. , Jan. 02, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it has signed a Letter of Intent with the National Center for